Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Kidney Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Renal Cell Carcinoma (358
)
Kidney Medullary Carcinoma (96
)
Renal Cell Carcinoma (358
)
Kidney Medullary Carcinoma (96
)
›
Associations
(387)
News
Trials
Search handles
@AldoLADETTINO
@AmandaNizamMD
@AndreaNecchi
@AzadOncology
@BenjaminBesseMD
@BourlonMaite
@BradMcG04
@BraunMDPhD
@CParkMD
@ChadTangMD
@ChapinMD
@ChungHanLee3
@DrChoueiri
@DrCraigGedye
@DrDanielHeng
@DrJJZhang
@DrRanaMcKay
@DrYukselUrun
@EnriqueGallar12
@EvanHallMD
@FAndreMD
@GGiannarini
@HHammersMD
@JadChahoud
@KMittalmd
@KidneyCancerDoc
@LindaMileshkin
@NagiSaghir
@NazliDizman
@OncoLucus
@PBarataMD
@PGrivasMDPhD
@PaulSargos
@PavlosMsaouel
@Prof_IanD
@RPachynski
@ReneeSaliby
@RicBertolo
@ShuchiGulati
@TiansterZhang
@VivekSubbiah
@_ShankarSiva
@apolo_andrea
@arihakimi
@brian_rini
@crisuarez08
@d_shapiro1
@drenriquegrande
@gbanna74
@hematologo
@jimhumd
@jsoriamd
@kakeegs3
@kdjhaveri
@montypal
@nataliagandur
@navstruck
@neerajaiims
@romeerizwan
@sonpavde
@tompowles1
@weoncologists
@yekeduz_emre
Search handles
@AldoLADETTINO
@AmandaNizamMD
@AndreaNecchi
@AzadOncology
@BenjaminBesseMD
@BourlonMaite
@BradMcG04
@BraunMDPhD
@CParkMD
@ChadTangMD
@ChapinMD
@ChungHanLee3
@DrChoueiri
@DrCraigGedye
@DrDanielHeng
@DrJJZhang
@DrRanaMcKay
@DrYukselUrun
@EnriqueGallar12
@EvanHallMD
@FAndreMD
@GGiannarini
@HHammersMD
@JadChahoud
@KMittalmd
@KidneyCancerDoc
@LindaMileshkin
@NagiSaghir
@NazliDizman
@OncoLucus
@PBarataMD
@PGrivasMDPhD
@PaulSargos
@PavlosMsaouel
@Prof_IanD
@RPachynski
@ReneeSaliby
@RicBertolo
@ShuchiGulati
@TiansterZhang
@VivekSubbiah
@_ShankarSiva
@apolo_andrea
@arihakimi
@brian_rini
@crisuarez08
@d_shapiro1
@drenriquegrande
@gbanna74
@hematologo
@jimhumd
@jsoriamd
@kakeegs3
@kdjhaveri
@montypal
@nataliagandur
@navstruck
@neerajaiims
@romeerizwan
@sonpavde
@tompowles1
@weoncologists
@yekeduz_emre
Filter by
Latest
9ms
1. Lessons from Melanoma: Building on PD1 backbone w/ CTLA/LAG3 (FS Hodi, @wolchokj, @MPostow) 2. What’s new in IrAE mgmt? @DrJNaidoo @CardioOncology @kreynoldsMD 3. RCC Germline Genetics: Past, Present, Future (Linehan,@KidneyCancerDoc @pearldaily) 4. @kidneycan FallAdvocacy (@MikeSerzanMD)
9 months ago
IO biomarker
|
PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3)
9ms
Could the design of CONTACT-03 have been improved with a PD-1 rather than a PD-L1? @PBarataMD shares his thoughts on this and other aspects of CONTACT-03 in our recent roundtable...https://t.co/8787qeeN80 #kidneycancer (@GUOncologyNow)
9 months ago
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
9ms
Beautiful paper from @ggebraelmd, mentored by @neerajaiims @huntsmancancer, on the heels of his fantastic presentation at #KCRS23! Whether #kidneycancer or #prostatecancer, his command of the science and literature are amazing!!! @NeliMUlrich (@montypal)
9 months ago
9ms
As a patient advocate, agree we need prospective trials. Would have hoped to see #QoL as an endpoint given the potential to delay/avoid systemic toxicities for oligomet #kidneycancer patients. Hugely important for patient decision making. (@DebMaskens)
9 months ago
Clinical
9ms
Congratulations to the lab of @BraunMDPhD! The team has received approximately $5.75M in funding from @theNCI and @DeptofDefense to investigate the immune microenvironment of renal cell carcinoma. #RCC #kidneycancer #cancerresearch @YaleMed @SmilowCancer https://t.co/Y4ssOlviGt (@YaleCancer)
9 months ago
9ms
NEW KIDNEY MODEL WITH BLOOD PERFUSION 🩸 Please, take a look! @prokarurol @AntonioAlcarazA @vital_hevia @DrJM_Gaya @DrVitagliano😉 What do you think about it? #RAPN #kidneycancer #urology #surgery #partialnephrectomy https://t.co/HnzL6a3wL8 (@urotrainer)
9 months ago
Surgery
9ms
🎥@BraunMDPhD of @YaleMed discusses the unique immune biology of kidney cancer and the need for targeted studies to understand resistance and improve anti-tumor immunity: ➡️https://t.co/xvWEtPBhOk #KCSM #ASCO23 #ImmunoOnc (@VJOncology)
9 months ago
9ms
Great group for a great cause! @KidneyCancer (@kakeegs3)
9 months ago
9ms
Amazing few days in Cuyuna, MN on a MTB trip with @BradLeibovichMD @kakeegs3 @wandering_gu My first MTB experience. And I’m hooked What a blast and thankful for great friends to spend some time with @MayoUrology @KidneyCancer @MDAndersonNews @UMichUrology @VUMCurology (@ChapinMD)
9 months ago
9ms
Now I’m curious if this is a figure of speech or if @KidneyCancerDoc and @chrisfilson_uro will be working on perfecting their roundhouse kicks together. (@KBGinsburg)
9 months ago
9ms
Medical professionals give insight into new medications coming out for patients with kidney cancer, explained by @DrRanaMcKay. https://t.co/59YeE9WhOd (@cure_today)
9 months ago
Clinical
9ms
Comparing the cost-effectiveness of immunotherapy-based regimens and sunitinib in treating metastatic #RenalCellCarcinoma from a public payer perspective. Manish Kohli, MD @huntsmancancer joins @PBarataMD @caseccc to discuss on UroToday > https://t.co/pKTfVnZcwj @JCOOP_ASCO (@urotoday)
9 months ago
Clinical • HEOR • Cost effectiveness • Metastases
|
Sutent (sunitinib)
9ms
A Predictive Model for Kidney Failure After Nephrectomy for Localized Kidney Cancer: The Kidney Cancer Risk Equation https://t.co/WOX9PwMbAN @OksanaH12 @JayNayakMD @nickgrubic @ThomasFerg28 @Msood99M @NavTangri @SevenOaksCDIC @ICESOntario (@AJKDonline)
9 months ago
9ms
Watch our Dr. Eric Jonasch discuss second-line treatment options for advanced clear cell renal cell carcinoma: https://t.co/xnPcaDgj40 @OncLive @Ejonasch #KidneyCancer #EndCancer (@MDAndersonNews)
9 months ago
Clinical • Metastases
9ms
8b/16 #TumorBoardTuesday #RCC @QingZhangLab #KidneyCancer ✨TiNivo-2: 📚@DrChoueiri @AlbigesL @HHammersMD @DrRanaMcKay @DrDanielHeng @motzermd https://t.co/UbPQeV5LgU (@katy_beckermann)
9 months ago
9ms
CONTACT-3 clearly shows the addition of atezolizumab to cabozantinib is no better than cabo alone in advanced renal cancer patients who have had PD on PD1 therapy. It seems to add to toxicity with no subset benefiting. (@tompowles1)
9 months ago
Clinical • Metastases
|
Tecentriq (atezolizumab) • Cabometyx (cabozantinib tablet)
9ms
12/16 #TumorBoardTuesday #RCC #KidneyCancer ✨SOAR✨ 📌Prospective trial to study SBRT vs systemic therapy ☢️Radiation therapy by SBRT can provide 90% disease control rate. ‼️ENROLLMENT OPENS August ‘23‼️ 📚https://t.co/xAbOA4D8tA (@katy_beckermann)
9 months ago
Clinical
9ms
15b/16 #TumorBoardTuesday #RCC #KidneyCancer 👨🏻🔬 An additional trials are developing HIF inhibitors ✨Ph1 AB521: https://t.co/MiZKHmXp7b (@katy_beckermann)
9 months ago
9ms
14/16 #TumorBoardTuesday #KidneyCancer #RCC 📌VHL Syndrome 🧬Genetically inherited RCC with VHL mut 💊PO belzutifan blocks HIF: 49% ORR with time to tx response ➡️ 8 mos 🔹Loss of VHL function drives 90% of sporadic ccRCC via upregulation of HIF @VHLAlliance (@katy_beckermann)
9 months ago
Welireg (belzutifan)
9ms
#TumorBoardTuesday No laughing but I keep a folder at my desk for virtual tumor board at my institution because hereditary syndrome associated with renal tumors are not common 😁 - they say germline mutations are in 5% of RCC (@HannahAlison20)
9 months ago
9ms
@MosheOrnsteinMD @AJangMD @AmandaNizamMD @scserendipity1 @drrosenbergmsk @JonAnker1 @DRBakaloudiMD @JVentoMD @RahulBanerjeeMD @YuWeiChenMD @ReneeSaliby @LisaHenske @QingZhangLa @neerajaiims @KidneyCancerDoc @vinay_onc @DanLinMD @HibaMKhanMD @DrJohnSfakianos @PBarataMD @sonpavde (@katy_beckermann)
9 months ago
9ms
🌟 New blog! An in-depth look at the impact of gut microbiome manipulation on drug efficacy and clinical trial stratification in #kidneycancer from #ASCO23. Feat @EbrahimiHedyeh @derosa__lisa @mcquadeMDLAc #ThomasGajewski #ShahlaBari. Story by @DAnnGeorge1 https://t.co/XFAjP5gg7W (@KidneyCancer)
9 months ago
Clinical
9ms
Quick #ACSCancerChat question to @drfrankiejs, @tompowles1, and Dr. Matthew Young. What are current challenges & limitations in the use of immune checkpoint inhibitors🧪 in the adjuvant setting for renal cell carcinoma #KidneyCancer ? @OncoAlert 🚨 @VivekSubbiah @WalterStadler5 (@weoncologists)
9 months ago
Clinical • Checkpoint inhibition
9ms
The #CaboPoint Study: Cabozantinib after checkpoint inhibitor therapy in patients with advanced #RenalCellCarcinoma. @AlbigesL @GustaveRoussy joins @PBarataMD @caseccc to discuss on UroToday > https://t.co/X7GyjvNnuO @ExelixisInc (@urotoday)
9 months ago
Clinical • Checkpoint inhibition • Metastases
|
Cabometyx (cabozantinib tablet)
9ms
Overall survival and efficacy results of second-line treatment for patients with metastatic clear cell #RenalCellCarcinoma. Yann-Alexandre Vano, MD @HopitalPompidou joins @PBarataMD @caseccc to discuss the results of the #BIONIKK trial on UroToday > https://t.co/weFQlBD0Ww (@urotoday)
9 months ago
Clinical • Metastases
9ms
.@DrTHut forecasts the future of #kidneycancer combination regimens. Will triplets or even quadruplets move treatment forward? @TexasOncology https://t.co/wbh6kd8SCY (@GUOncologyNow)
9 months ago
9ms
At #ASCO23, IO/TKI vs IO/IO took center stage for metastatic #kidneycancer. Which is best for patients long-term? @DrTHut of @TexasOncology tells us where he stands... https://t.co/blayc66nv6 (@GUOncologyNow)
9 months ago
Clinical • Metastases
9ms
#BeyondTheAbstract! This systematic review and meta-analysis highlights the potential of immune checkpoint inhibitors as adjuvant treatment for #RenalCellCarcinoma. Learn more about the promising result with @fsabino_onco on UroToday > https://t.co/8M6BaRkDxc @LACOG_group (@urotoday)
9 months ago
Retrospective data • Review • Checkpoint inhibition
9ms
Im going through a similar journey to @THEJamesWhale myself and it can be lonely, frightening and weirdly life changing @kidneycanceruk (@gerardfinewine)
9 months ago
10ms
Great photo of one amazing #kidneycancer advocate! Oh, and of you too @HHammersMD Thank you both for the continued partnership, support, collaboration with patients and caregivers. @kidneycan (@DebMaskens)
10 months ago
Clinical • Licensing / partnership
10ms
Thank you @teekayowo for the opportunity to speak on #kidneycancer — was wonderful being part of the fantastic @UPMCHillmanCC symposium & seeing my parents in Pittsburgh was an amazing bonus!! Thanks for the memories!! https://t.co/frp2geja1j (@TiansterZhang)
10 months ago
10ms
Aprendiendo del mejor 🤩@drenriquegrande #kidneyCancer #TNE (@laurabolgue)
10 months ago
10ms
Please join us for the first #WiRCC women in RCC webinar 7/26 7:30 EST! Looking forward to talks from @BusyMomMD and @bergsa83. Let’s amplify! @KidneyCancer @kidneycan @kcCURE @HemOncWomenDocs @DrVaishampayan (@TiansterZhang)
10 months ago
10ms
Great discussion- this quote should be part of it: disease recurrence (captured by DFS) is a clinically meaningful endpoint that patients with kidney cancer appear to value as much as OS (@nativbklyn24)
10 months ago
Clinical
10ms
🏆 KEYNOTE ADDRESS 🏆 💫New Directions in Basic Kidney Cancer Research 🔬 Lessons from the past, Visions for the Future! @kaelin_lab @OncoAlert @kidneycan #KCRS23 (@MikeSerzanMD)
10 months ago
10ms
.@DrRanaMcKay from @UCSanDiego sat down to review the use of novel therapies in kidney cancer during @kidneycan (@CancerNetwrk)
10 months ago
Review
10ms
@kaelin_lab @NobelPrize laureate lecture was both informative and inspiring. He gave us a glimpse of the past and future of kidney cancer research, and it's clear that there are some exciting things on the horizon. I'm confident that the research that's being done today will lead… https://t.co/z6becmGWOj (@DrYukselUrun)
10 months ago
10ms
💫✨Spectacular talk!! 👏👏"New Directions in Basic Kidney Cancer Research" presented by Dr. William G. Kaelin, Jr., Nobel Laureate, Harvard Medical School @DanaFarber @kaelin_lab @NobelPrize @DrChoueiri @kidneycan @IKCCorg #kcrs23 #KCRS23 (@nataliagandur)
10 months ago
10ms
Beuatiful and inspiring talk by the Nobel laureate Dr. William Kaelin @kaelin_lab about new directions in basic kidney cancer research and drug development, highlighting the importance of drug combinations in order to try to improve cure rates. #KCRS23 (@FabioSchutz78)
10 months ago
10ms
@kaelin_lab @NobelPrize laureate lecture was both informative and inspiring. He gave us a glimpse of the past and future of kidney cancer research, and it's clear that there are some exciting things on the horizon. I'm confident that the research that's being done today will lead… https://t.co/b41AvQI2GB (@DrYukselUrun)
10 months ago
10ms
The excitement is palpable in the air as the keynote speaker takes the stage. He is a world-renowned expert in kidney cancer research, and his work has helped to revolutionize the way we understand and treat this disease. @kaelin_lab @DrChoueiri @tompowles1 @kidneycan #KCRS23… https://t.co/9UlV7CkGmZ (@DrYukselUrun)
10 months ago
10ms
The excitement is palpable in the air as the keynote speaker takes the stage. He is a world-renowned expert in kidney cancer research, and his work has helped to revolutionize the way we understand and treat this disease. @kaelin_lab @DrChoueiri @tompowles1 @kidneycan #KCRS23… https://t.co/ujsVNccXky (@DrYukselUrun)
10 months ago
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login